Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Assessment of Dual Antiplatelet Therapy Versus Rivaroxaban In Atrial Fibrillation Patients Treated With Left Atrial Appendage Closure: The Randomized ADRIFT Study

Trial Profile

Assessment of Dual Antiplatelet Therapy Versus Rivaroxaban In Atrial Fibrillation Patients Treated With Left Atrial Appendage Closure: The Randomized ADRIFT Study

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 22 Sep 2017

At a glance

  • Drugs Rivaroxaban (Primary) ; Aspirin; Clopidogrel
  • Indications Atrial fibrillation
  • Focus Therapeutic Use
  • Acronyms ADRIFT
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 19 Sep 2017 Planned End Date changed from 20 Dec 2018 to 23 Dec 2018.
    • 19 Sep 2017 Planned primary completion date changed from 20 Sep 2018 to 23 Sep 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top